PURPOSE: Radioligand binding studies indicate a down-regulation of myocardial beta(1)-adrenoceptors (beta(1)-AR) in cardiac disease which may or may not be associated with a decrease in beta(2)-ARs. We have chosen ICI 89,406, a beta(1)-selective AR antagonist, as the lead structure to develop new beta(1)-AR radioligands for PET and have synthesised a fluoro-ethoxy derivative (F-ICI). METHODS: (S)-N-[2-[3-(2-Cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-N'-[4-(2-[(18)F]fluoro-ethoxy)-phenyl]-urea ((S)-[(18)F]F-ICI) was synthesised. Myocardial uptake of radioactivity after intravenous injection of (S)-[(18)F]F-ICI into adult CD(1) mice or Wistar rats was assessed with positron emission tomography (PET) and postmortem dissection. Metabolism was assessed by high-performance liquid chromatography analysis of plasma and urine. RESULTS: The heart was visualised with PET after injection of (S)-[(18)F]F-ICI but neither unlabelled F-ICI nor propranolol (non-selective beta-AR antagonist) injected 15 min after (S)-[(18)F]F-ICI affected myocardial radioactivity. Ex vivo dissection demonstrated that predosing with propranolol or CGP 20712 (beta(1)-selective AR-antagonist) did not affect myocardial radioactivity. Radiometabolites rapidly appeared in plasma and both (S)-[(18)F]F-ICI and radiometabolites accumulated in urine. CONCLUSIONS: Myocardial uptake of (S)-[(18)F]F-ICI after intravenous injection was mainly at sites unrelated to beta(1)-ARs. (S)-[(18)F]F-ICI is not a suitable beta(1)-selective-AR radioligand for PET. (c) 2010 Elsevier Inc. All rights reserved.
PURPOSE: Radioligand binding studies indicate a down-regulation of myocardial beta(1)-adrenoceptors (beta(1)-AR) in cardiac disease which may or may not be associated with a decrease in beta(2)-ARs. We have chosen ICI 89,406, a beta(1)-selective AR antagonist, as the lead structure to develop new beta(1)-AR radioligands for PET and have synthesised a fluoro-ethoxy derivative (F-ICI). METHODS:(S)-N-[2-[3-(2-Cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-N'-[4-(2-[(18)F]fluoro-ethoxy)-phenyl]-urea ((S)-[(18)F]F-ICI) was synthesised. Myocardial uptake of radioactivity after intravenous injection of (S)-[(18)F]F-ICI into adult CD(1) mice or Wistar rats was assessed with positron emission tomography (PET) and postmortem dissection. Metabolism was assessed by high-performance liquid chromatography analysis of plasma and urine. RESULTS: The heart was visualised with PET after injection of (S)-[(18)F]F-ICI but neither unlabelled F-ICI nor propranolol (non-selective beta-AR antagonist) injected 15 min after (S)-[(18)F]F-ICI affected myocardial radioactivity. Ex vivo dissection demonstrated that predosing with propranolol or CGP 20712 (beta(1)-selective AR-antagonist) did not affect myocardial radioactivity. Radiometabolites rapidly appeared in plasma and both (S)-[(18)F]F-ICI and radiometabolites accumulated in urine. CONCLUSIONS: Myocardial uptake of (S)-[(18)F]F-ICI after intravenous injection was mainly at sites unrelated to beta(1)-ARs. (S)-[(18)F]F-ICI is not a suitable beta(1)-selective-AR radioligand for PET. (c) 2010 Elsevier Inc. All rights reserved.
Authors: T Wichter; M Schäfers; C G Rhodes; M Borggrefe; H Lerch; A A Lammertsma; F Hermansen; O Schober; G Breithardt; P G Camici Journal: Circulation Date: 2000-04-04 Impact factor: 29.690
Authors: Simon N Louis; Linda A Rezmann-Vitti; Tracy L Nero; Dimitri Iakovidis; Graham P Jackman; William J Louis Journal: Eur J Med Chem Date: 2002-02 Impact factor: 6.514
Authors: B Riemann; M P Law; K Kopka; St Wagner; S Luthra; V W Pike; J Neumann; U Kirchhefer; W Schmitz; O Schober; M Schäfers Journal: Nuklearmedizin Date: 2003-08 Impact factor: 1.379
Authors: Klaus Kopka; Stefan Wagner; Burkhard Riemann; Marilyn P Law; Carsten Puke; Sajinder K Luthra; Victor W Pike; Thomas Wichter; Wilhelm Schmitz; Otmar Schober; Michael Schäfers Journal: Bioorg Med Chem Date: 2003-08-05 Impact factor: 3.641
Authors: Marilyn P Law; Stefan Wagner; Klaus Kopka; Victor W Pike; Otmar Schober; Michael Schäfers Journal: Eur J Nucl Med Mol Imaging Date: 2007-09-29 Impact factor: 9.236
Authors: Heike S Radeke; Ajay Purohit; Thomas D Harris; Kelley Hanson; Reinaldo Jones; Carol Hu; Padmaja Yalamanchili; Megan Hayes; Ming Yu; Mary Guaraldi; Mikhail Kagan; Michael Azure; Michael Cdebaca; Simon Robinson; David Casebier Journal: ACS Med Chem Lett Date: 2011-07-22 Impact factor: 4.345